Member Info for Marty130

????

Surely we'll get better results next year, if not a possible takeover.

MFN status for Hvivo isn't clear and could affect our chances of new US contracts.

U2..

Down selling again.

2026 Outlook and Projections

Growth Trajectory: hVIVO expects a strong year of growth in 2026, building on new service lines and a diversified business model that now includes early-phase clinical research services (CRS).

Earnings Accretive: The company anticipates that its CRS division, acquired in 2024, will become earnings accretive in 2026.

Broker Confidence: Financial analysts at Shore Capital have expressed confidence in the company's 2026 rebound potential, noting a significant disconnect between the current market valuation and the long-term value of the business. The median analyst price target suggests a potential increase of over 150% from current levels.

Key Opportunities: hVIVO is pursuing several large contract opportunities that could solidify its recovery, including a potential record contract with ILiAD for a Phase III vaccine trial and another project with a major global pharmaceutical company.

Financial Health: As of June 30, 2025, hVIVO maintained a strong balance sheet with approximately £23 million in cash reserves and remains debt-free, providing a solid foundation for future investment and operations.

Key Event in 2026

J.P. Morgan Healthcare Week: hVIVO is scheduled to participate in the J.P. Morgan Healthcare Week event, which will take place from January 12-15, 2026, in San Francisco. This event provides an opportunity for the company to present its progress and future plans to a global audience.

Trending upwards, bodes well for 2026..

They do hold a lot of influence.

Also the ftse was down today. Which doesn't help. Under Trump, pharmaceuticals have gone through a rough time, apparently next year should be better than this year.

Broker backs hVIVO 2026 rebound: Shore Capital thinks hVIVO PLC (AIM:HVO) shares are worth far more than the market price, despite a bruising year for the stock. The broker has reiterated its Buy rating and set a fair value of 25p a share, more than five times the current price of 4.8p.

The investment case rests on an improving backdrop for biotechnology companies in the US and what that could mean for demand at hVIVO, a specialist contract research organisation.

Funding conditions for biotech have been weak since the pandemic boom faded. That has made companies cautious about starting new clinical trials. For hVIVO, this has shown up in a shrinking order book and contract cancellations over the past 18 months.

Shore Capital points to signs that the cycle may be turning. In one day this week, eight US biotech groups raised about $3.2 billion through follow-on share sales, a recent record.

The main biotech indices are up more than 30% this year, helped by takeover activity and licensing deals. Stronger...

Back up tomorrow.

Are you referring to another compan

German Market is huge.. Once the CE goes through, plenty will sign up.

Trades 265

Vol Sold 4,044,357

Vol Bought 3,522,198

52 Week High 21.10

52 Week High Date 27-Jan-2025

52 Week Low 4.35

52 Week Low Date 11-Dec-2025

# of Trades 251

Vol Sold 3,732,813

Vol Bought 3,379,968

52 Week High 21.10

52 Week High Date 27-Jan-2025

52 Week Low 4.35

52 Week Low Date 11-Dec-2025

Welcome to the AIM market! Though most analysts are suggesting the stock to keep rising in the coming months.

Nice to see this trending upwards. I imagine this will continue into the new year, with the wiz kid at the helm!

CE marks always add value.

Just added hVIVO to my portfolio.. Looks undervalued, may come into it's own in 26.. A possible takeover target could see increasing share holder value.

The current CRS leadership team will continue in their roles, working alongside hVIVO to implement growth initiatives. The Company expects the integration to yield strong revenue growth and a significant improvement in EBITDA margins by 2026.

hVIVO's CEO, Yamin 'Mo' Khan, expressed confidence in the acquisition, citing the potential for significant synergies and growth opportunities. Dr. Elisabeth Lackner, CEO of CRS, echoed this sentiment, highlighting the mutual benefits of the combined expertise and infrastructures.

This strategic move is part of hVIVO's aim to achieve a £100 million Group revenue target by 2028, with further small bolt-on acquisitions being considered. The information provided is based on a press release statement.